Lantheus Highlights New Radiodiagnostic Data at the 2026 SNMMI Annual Meeting
Lantheus Holdings, Inc., a leading radiopharmaceutical company, announced it will present new clinical data on its radiodiagnostic products at the 2026 Society of Nuclear Medicine and Medical Imaging Annual Meeting. The data highlights advancements in prostate cancer management using PSMA-PET with Piflufolastat F18 and diagnostic performance of 18F…